Skip to main content
All lobbying filings

EDWARDS LIFESCIENCES, LLC

Lobbying for EDWARDS LIFESCIENCES LLC

 Filing 4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Expenses
$350,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 5
  • Centers For Medicare and Medicaid Services (CMS)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Lobbying activity 3
Health Issues

Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials

Medicare/Medicaid

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Trade (domestic/foreign)

Japan Reimbursement of Medical Devices

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem